Aft banks on stronger second half as strike and destocking hit first-half result

Aft banks on stronger second half as strike and destocking hit first-half result
Hartley Atkinson says Aft should have a new licensing deal for its Maxigesic pain relief soon. (Image: Aft Pharmaceuticals)
Rebecca Stevenson
Aft Pharmaceuticals is pinning its hopes on a stronger second-half result after a $2.46 million loss for the six months to Sept 30. The New Zealand Exchange (NZX) listed pharmaceutical manufacturer said its result was affected by a doctor strike in South Korea and several large customers reducing stock. These caused a $6.5m hit to product sales and royalties in Aft’s Asian and other international markets, the company said.Sales of its Maxigesic intravenous line were significantly affected by the now-resolved doctors' strike....

More Markets

NZ sharemarket edges higher as F&P Healthcare weighs on gains
Markets Market Close

NZ sharemarket edges higher as F&P Healthcare weighs on gains

The S&P/NZX 50 Index closed 14.49 points or 0.11% down at 13,391.59.

Jamie Gray 24 Oct 2025
Contact Energy expands global investor base
Markets

Contact Energy expands global investor base

Contact Energy priced an inaugural €500 million (NZ$1.01b) 7-year senior bond under its Euro Medium Term Note (EMTN) Programme, it said Friday.“This marks a milestone in Contact’s funding strategy, expanding our global investor base and reinforcing our commitment to sustainable f...

Rebecca Howard 24 Oct 2025
Kiwibank wary of capital-review barrier to growth
Finance

Kiwibank wary of capital-review barrier to growth

Kiwibank raises issues of competitive advantage.

Andy Macdonald 24 Oct 2025
Fonterra windfall brings risks: ASB
Primary Sector

Fonterra windfall brings risks: ASB

Farmers will vote for the Lactalis deal on Oct 30.

Rebecca Howard 24 Oct 2025